Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT03470545Phase 3Completed
- Sponsor
- MyoKardia
- Start
- May 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Started May 2018; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT03470545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03470545.